In:
Canadian Journal of Physiology and Pharmacology, Canadian Science Publishing, Vol. 83, No. 8-9 ( 2005-08-01), p. 785-790
Abstract:
To clarify the beneficial effects of cilnidipine, an L- and N-type calcium channel blocker, which were clinically observed against diastolic dysfunction in hypertrophied hearts of hypertensive patients, we investigated the effects of cilnidipine on cardiac remodeling and enhanced gene expression in stroke-prone, spontaneously hypertensive rats in comparison with that of captopril, a well-known angiotensin-converting enzyme inhibitor, at threshold doses with little blood pressure lowering effect. The expression of type III collagen and β/α-myosin heavy chain as well as transforming growth factor-β, and basic fibroblast growth factor were suppressed by both treatments, indicating the prevention or amelioration of cardiac dysfunction. Such beneficial effects were much more intense with cilnidipine treatment than in captopril. These results indicate that Ca 2+ is a key factor in the pathogenesis of cardiac remodeling in hypertension. One possible beneficial effect of cilnidipine in the prevention of cardiac dysfunction may be due to the decreased amount of growth factors such as transforming growth factor-β and basic fibroblast growth factor via direct action for Ca 2+ influx and also via inhibition of local renin-angiotensin system in the myocardium.Key words: hypertension, cardiac hypertrophy, Ca 2+ -blocker, growth factor.
Type of Medium:
Online Resource
ISSN:
0008-4212
,
1205-7541
Language:
English
Publisher:
Canadian Science Publishing
Publication Date:
2005
detail.hit.zdb_id:
2004356-9
Permalink